Effect of indomethacin on estrogen-induced luteolysis in the ewe

Oxytocin stimulated release of PGF2α and its inhibition by a cyclooxygenase inhibitor and an oxytocin receptor antagonist from equine endometrial cultures

Uterine inflammation results in a poor uterine environment and early embryonic loss in the mare due to an inhibition of maternal recognition of pregnancy caused from increased prostaglandin F2α (PGF2α). Oxytocin binds to endometrial cell receptors to activate prostaglandin synthesis. An oxytocin receptor antagonist (Atosiban) and a cyclooxygenase inhibitor (indomethacin) both decrease PGF2α production. The aim of this study was to evaluate the in vitro effects of Atosiban and indomethacin on equine uterine prostaglandin secretion. Equine endometrial explants were harvested on day two of behavioral estrus. Endometrial explant cultures were challenged with oxytocin (250nM) and PGF2α concentrations were measured over time. Explants were also cultured with Atosiban and indomethacin for 6h to determine the influence on PGF2α secretion. When endometrial explants were challenged with oxytocin, PGF2α concentrations were greater (P<0.0001) at each time point over the 24h of culture as compared to controls. Oxytocin failed (P<0.001) to elicit PGF2α release in explants cultured with either Atosiban or indomethacin. These findings show equine endometrial explants can be stimulated with oxytocin to increase secretion of PGF2α and this secretion can be inhibited through an oxytocin receptor antagonist and a Cox inhibitor, suggesting that this response to oxytocin involves an oxytocin receptor mediated event that activates the prostaglandin synthesis cascade through cyclooxygenase. Furthermore, this data suggests a role for the use of these inhibitors in vivo to decrease uterine PGF2α secretion and prevent early luteal regression and embryonic loss.

Effect of indomethacin administration on glucose homeostasis and pancreatic hormones in lactating goats

To determine glucogenic and hormonal responses in ruminants to indomethacin, a prostaglandin synthetase inhibitor, four lactating Toggenburg goats were used in a crossover design. Fifteen milligrams of indomethacin or 3 ml of saline were injected subcutaneously twice daily with propionate infused intrajugularly at a rate of 2 mM/min for 75 min as a challenge. Plasma glucose concentrations were increased by indomethacin injections. Plasma concentrations of insulin, glucagon, and 6-keto-prostaglandin F1 alpha were not affected by indomethacin injections. Propionate infusion elevated plasma glucose, insulin, and glucagon concentrations. A decreased insulin release in response to propionate challenge was observed with indomethacin injections.

Effects of systemic administration of indomethacin to cyclic ewes on endometrial concentrations of prostaglandins effects on estrous cycle length and on progesterone, luteinizing hormone and prolactin patterns

Experiments were designed to evaluate in cyclic sheep the effects of systemic administration of a prostaglandin synthetase inhibitor (Indomethacin). Indomethacin (100 mg, 3 times daily, S.C.) was administered from day 7 of the estrous cycle for 16 days to five ewes in which the cycle was synchronized as well as the cycles of five control ewes. All control ewes had cycles of approximately 17 days duration, but three of five Indomethacin treated ewes showed no estrous behavior before their slaughter at 23 days after induced ovulation. Autopsy revealed normal corpora lutea which had not undergone luteolysis, as confirmed by progesterone determination in blood. The two remaining Indomethacin treated ewes showed an estrous behavior on day 19 and 20 respectively together with a "preovulatory surge" of luteinizing hormone and prolactin which was not followed by follicular rupture. These results show that inhibition of PGF2 alpha synthesis by systemic administration of Indomethacin to the ewe is able to prevent luteolysis. When luteolysis did occur however, it was not followed by an ovulation despite a normal gonadotropin surge, indicating that inhibition of prostaglandin synthesis by systemic administration of Indomethacin interferes with the luteolysis and follicle rupture processes.